Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2011. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility (PDMRs), or connected persons, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific share transactions rather than a financial performance report.
Material Changes
On May 5, 2011, the Administrators of the US Retirement Savings Plan notified the registrant of an increase in the notional allocation of Ordinary Share ADRs following a re-valuation of the cash element of the notional investment. The transaction price was $42.87 per ADR.
Management Commentary and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly details the notification of share allocations in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
Important Facts for Investors
- Transaction Date: May 5, 2011 (Notification date: May 6, 2011).
- Transaction Type: Increase in notional allocation of Ordinary Share ADRs within the US Retirement Savings Plan.
- Price per ADR: $42.87.
- Individual Allocations:
- Dr M M Slaoui: 9 shares
- Dr K Slaoui (Connected Person): 7 shares
- Mr W C Louv: 15 shares
- Dr D Pulman: 27 shares
- Mr E J Gray: 21 shares
- Ms D Connelly: 1 share
- Financial Data: No financial performance metrics are included in this specific filing.